bio sketch column
Bridget Wagner is the director of Pancreatic Cell Biology and Metabolic Disease in the Center for the Science of Therapeutics at the Broad Institute. Her group's research focuses on identifying small molecules capable of increasing pancreatic beta cell number and function, with the ultimate goal of treating diabetes. Beta-cell death, and the consequent deficiency in insulin secretion, is a key feature of type 1 diabetes. For decades, the standard of care for this disease has been insulin therapy by intramuscular injection. While cell-based treatments show promise, a chemical intervention capable of restoring glycemic control in type 1 diabetes would have enormous impact clinically, by enabling an in vivo pancreatic effect while avoiding the need for immunosuppression. Wagner’s group is developing phenotypic cell-based assays to find compounds that increase human beta cell proliferation, that can protect beta cells from the inflammatory processes of diabetes progression, or that can induce other cells in the pancreas to take over the role of beta cells by producing insulin themselves. Wagner received an AB from Harvard College and a PhD from Harvard University, working with Stuart Schreiber.